Quoin Pharma Submits U.S. Patent for New Skin Disease Treatments

Quoin Pharmaceuticals Ltd., based in Ashburn, Virginia, has recently filed a patent application in the United States for innovative topical formulations aimed at treating several rare skin disorders, including Netherton Syndrome (NS). This development is part of Quoin's broader efforts to address rare and orphan diseases through specialized therapeutic products. The company is actively testing its leading formulation, QRX003, in four different clinical trials targeting Netherton Syndrome. Notably, three of these trials are being conducted under an open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

The ongoing clinical trials include studies in pediatric patients at the Children’s Hospital in Dublin, Ireland, with plans to extend this research to additional countries such as Spain and the United Kingdom. Quoin has reported promising initial results from two of these open-label studies, which demonstrate the potential effectiveness of QRX003. Importantly, there are currently no FDA-approved treatments available for either Netherton Syndrome or Peeling Skin Syndrome, underscoring the significance of this research.

Beyond Netherton Syndrome, Quoin’s recent patent application also encompasses Peeling Skin Syndrome, another rare condition for which the company is conducting a clinical study in New Zealand involving pediatric patients. The lack of approved treatments for these rare disorders highlights the potential impact of Quoin's research and development efforts in these areas.

Dr. Michael Myers, the Chief Executive Officer of Quoin, emphasized the company's commitment to completing the clinical trials for QRX003 in treating Netherton Syndrome. He also highlighted the strategic importance of securing extensive patent protection for QRX003 to cover not only Netherton Syndrome but other rare skin disease applications that the company is targeting. If approved, the patent would secure Quoin's intellectual property rights for QRX003 until 2045.

Currently, Quoin is actively enrolling participants in three clinical trials conducted under their open IND application, which are evaluating the efficacy of QRX003 as a treatment for Netherton Syndrome. Quoin stands out as the only company recruiting and testing a significant number of subjects in multiple NS clinical trials under an open IND, demonstrating its leadership in this specialized field.

Quoin Pharmaceuticals Ltd. is a clinical-stage company devoted to developing and commercializing treatments for rare and orphan diseases. Its innovative pipeline includes five products in various stages of development, targeting a diverse array of rare conditions. These include Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, among others. The company is dedicated to meeting unmet medical needs, providing relief to patients, families, healthcare providers, and communities affected by these diseases.

In conclusion, Quoin Pharmaceuticals is making significant strides in the field of rare skin diseases with its groundbreaking approaches and therapies. The company's focus on securing patent protection and expanding its clinical trials internationally reflects its commitment to offering new hope to those affected by conditions with limited treatment options currently.